TherapeuticsMD (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

TXMD has been the subject of several other research reports. BidaskClub cut shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research note on Tuesday. reaffirmed a “buy” rating and set a $14.00 price objective on shares of TherapeuticsMD in a research note on Tuesday, February 12th. Oppenheimer set a $14.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Monday, February 11th. ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Sunday, February 10th. Finally, Noble Financial reaffirmed an “outperform” rating and set a $13.00 price objective on shares of TherapeuticsMD in a research note on Tuesday, April 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $12.75.

TXMD opened at $3.31 on Tuesday. TherapeuticsMD has a twelve month low of $3.19 and a twelve month high of $7.66. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.39 and a quick ratio of 3.28. The stock has a market cap of $796.03 million, a P/E ratio of -5.61 and a beta of 1.96.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. TherapeuticsMD had a negative net margin of 907.71% and a negative return on equity of 159.71%. The firm had revenue of $3.95 million during the quarter, compared to the consensus estimate of $5.96 million. During the same quarter in the prior year, the firm earned ($0.11) EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. On average, sell-side analysts expect that TherapeuticsMD will post -0.64 earnings per share for the current fiscal year.

In related news, Director Jules A. Musing sold 17,400 shares of the company’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $5.80, for a total transaction of $100,920.00. Following the completion of the sale, the director now owns 5,000 shares of the company’s stock, valued at approximately $29,000. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 22.85% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. We Are One Seven LLC purchased a new stake in TherapeuticsMD during the 4th quarter valued at about $26,000. Private Ocean LLC purchased a new stake in TherapeuticsMD during the 1st quarter valued at about $37,000. Advisor Group Inc. grew its stake in TherapeuticsMD by 163.4% during the 1st quarter. Advisor Group Inc. now owns 8,060 shares of the company’s stock valued at $38,000 after acquiring an additional 5,000 shares in the last quarter. Dfpg Investments Inc. purchased a new stake in TherapeuticsMD during the 4th quarter valued at about $38,000. Finally, Menta Capital LLC purchased a new stake in TherapeuticsMD during the 1st quarter valued at about $56,000. 80.03% of the stock is owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Featured Story: What Does a Sell-Side Analyst Rating Mean?

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.